|1.||Rosenberg, Steven A: 7 articles (10/2010 - 01/2002)|
|2.||Rivoltini, Licia: 5 articles (03/2007 - 06/2002)|
|3.||Parmiani, Giorgio: 5 articles (03/2007 - 06/2002)|
|4.||Ferrone, Soldano: 4 articles (06/2013 - 04/2004)|
|5.||Sasaki, K: 4 articles (08/2002 - 08/2000)|
|6.||Inokuma, H: 4 articles (08/2002 - 08/2000)|
|7.||Onishi, T: 4 articles (08/2002 - 08/2000)|
|8.||Khatlani, T S: 4 articles (08/2002 - 08/2000)|
|9.||Rosenberg, S A: 4 articles (11/2001 - 01/2000)|
|10.||Moss, Joel: 3 articles (03/2015 - 01/2008)|
08/01/2005 - "Approximately 70% of the animals were cured from existing tumors by treatment with alphaDEC conjugates carrying two different melanoma antigens (TRP-2 and gp100). "
04/01/2009 - "The key finding in this study is that protection from freshly implanted or established B16 tumors is primarily mediated by TRP1(222)-specific CTL and not by CTL specific for more traditional melanoma antigens such as TRP2 or gp100. "
06/01/2013 - "Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells."
11/01/2011 - "Here, we reconstituted the yeast-expressed gp96 (recombinant gp96, rgp96) with B16.F10 melanoma antigens in vitro to prepare new gp96 tumor vaccine on large-scale, and analyzed its induction of specific anti-tumor immunoresponses by ELISPOT, IFN-gamma intracellular staining and cytotoxicity assays. "
01/01/2010 - "Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses."
|2.||Melanoma (Melanoma, Malignant)
01/01/2003 - "Thus, the authors have undertaken these studies in patients with metastatic melanoma undergoing immunizations with known melanoma antigens. "
01/01/2001 - "Anti-melanoma immunization trials were performed in patients, through dendritic cells charged with melanoma antigens. "
01/01/1983 - "The objectives of this study are to demonstrate the specificity of sera from melanoma patients undergoing autologous immunization and to localize melanoma antigens on a cellular level. "
08/01/2014 - "Activating PD-1 triggers an immune checkpoint resulting in inhibition of T cells directed against melanoma antigens and prevents the immune system from combating the melanoma. "
10/01/2013 - "Third, MAPK inhibition upregulates the expression of some melanoma antigens and, therefore, may enhance T-cell recognition of vemurafenib-treated melanomas. "
|3.||Neoplasm Metastasis (Metastasis)
02/01/2003 - "Our findings that these FAP-positive structures showed no overlap with endothelial cell surface markers, nor with various melanoma antigens, suggest that FAP is a marker for specific stromal-cell-derived patterns in cutaneous melanoma metastases."
09/01/2013 - "The genetic aberrations of these tumours closely resemble those of cutaneous melanomas, and therefore are suggestive of spontaneous regressions of the primary tumours.3.Both primary tumours and metastases often have brisk lymphocytic infiltrates, a phenomenon that is correlated with better outcome.4.Studies of isolates of these tumour-infiltrating T lymphocytes have revealed that a proportion of these cells recognise melanoma antigens.5.Melanomas respond to immunotherapy. "
11/01/2001 - "Expression of melanoma antigens and HLA was measured by laser scanning cytometry and immunohistochemistry in fine-needle aspirates from melanoma metastases. "
|4.||Testicular Neoplasms (Testicular Cancer)
05/01/2012 - "Therapeutic targeting of melanoma antigens frequently focuses on the melanocyte differentiation or cancer-testis families. "
01/01/2014 - "A trial of a vaccine as adjuvant therapy for patients with completely resected NSCLC is also ongoing with one of the major cancer-testis antigens, melanoma-associated antigen (MAGE)-A3. "
12/01/2003 - "In this study, we provide evidence that two common murine glioma cell lines (GL26 and GL261) express the melanoma antigens gp100 and tyrosinase-related protein 2 (TRP-2). "
01/01/1991 - "Major categories of glioma cell antigens include glial antigens, ECM antigens, muscle antigens, melanoma antigens, "tumor-specific" antigens, and cellular proliferation antigens. "
|1.||T-Cell Antigen Receptors (T-Cell Receptor)
|3.||Monophenol Monooxygenase (Tyrosinase)
|6.||Ki-67 Antigen (Ki 67 Antigen)
|10.||Proteins (Proteins, Gene)
|3.||Drug Therapy (Chemotherapy)